Biotech Values

[DewDiligence]

ARIA—Notwithstanding your friend’s professional analysis, I would opine that investigator bias is still the major explanation for the discrepancy in the Rida trial.

In the history of clinical trials for drugs and medical devices, when central examiners and on-site investigators have disagreed to a material degree about the measurement of an efficacy metric, the data from the investigators has in every instance been more bullish for the drug or device being studied. This suggests to me that post hoc attempts to attribute such a discrepancy to a different cause, such as the one you cited in your post, should probably not be taken seriously by investors. Regards, Dew